➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Dow
McKinsey
Express Scripts
Merck

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,572,484

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,572,484
Title:System and method for providing analysis of visual function using a mobile device with display
Abstract: A visual function evaluation is performed using a sequence of interactions with a mobile device. A patient user may perform a variety of visual tests using the mobile device. The mobile device transmits the test results to a remote server implementing analysis of the visual function results using network service. The network service receives the test results, processes the results, and provides the processed results to a healthcare provider. The processed results may include trends of the user\'s visual function test performance. The healthcare provider, such as a physician, may optimize and administer treatment based on the data. Early detection of changes in visual function can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense.
Inventor(s): Palanker; Daniel (Palo Alto, CA), Blumenkranz; Mark (Los Altos Hills, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University (Stanford, CA)
Application Number:15/090,080
Patent Claims:1. A method for performing analysis of a visual function of a user with a retinal disease who is receiving recurrent treatment from a healthcare provider, comprising: receiving the user's visual function test data from a remote mobile device application; executing a test data analysis module stored in memory by a processor, the executed test data analysis module processing the visual function test data to generate a trend data of visual function and analyzing the trend data of visual function based on the retinal disease of the user to determine the user's response to treatment, need for treatment, or need for evaluation by a healthcare provider; transmitting the visual function test data and the trend data to a remote computing device; and predicting a time for the next treatment for the user based on the trend data of visual function.

2. The method of claim 1, further comprising: receiving a message from a physician for the user; and transmitting the message to the remote computing device.

3. The method of claim 1, further comprising: transmitting the predicted time for the next treatment to the remote computing device.

4. The method of claim 1, further comprising: analyzing the trend data of visual function and comparing the trend data to previous trend data for the user.

5. The method of claim 4, further comprising: transmitting an alert to the remote computing device if the trend data of visual function is outside of a range of acceptable variation in comparison to the previous trend data for the user.

6. The method of claim 1, further comprising: comparing the trend data of visual function to trend data aggregated for patients with a similar retinal disease to the user.

7. The method of claim 1, further comprising making visual function test data and the trend data available to the healthcare provider.

8. The method of claim 1, further comprising sending an alert to the healthcare provider if the change in visual function data is above a level specified by the healthcare provider.

9. The method of claim 1, further comprising making visual function test data and the trend data available on a secure webpage.

10. The method of claim 9, wherein the secure webpage is available to the user and the healthcare provider.

11. The method of claim 1, wherein the visual function test data corresponds to tests that were pre-selected for the user by the user's healthcare provider and performed by the user using the remote mobile device application.

12. The method of claim 11, wherein the one or more visual function tests are pre-selected by a healthcare provider based on analysis of retinal imaging of the user.

13. The method of claim 11, wherein the test is pre-selected by the healthcare provider based on the retinal disease or the recurrent treatment.

14. The method of claim 13, wherein the recurrent treatment comprises monitoring disease progression or administration of a pharmacological agent.

15. The method of claim 1, wherein the healthcare provider is a doctor, nurse, medical professional, or medical technician.

16. The method of claim 1, wherein the recurrent treatment includes an intraocular injection of a pharmacological agent.

17. The method of claim 16, wherein the pharmacological agent is a VEGF inhibitor.

18. The method of claim 17, wherein the VEGF inhibitor is Lucentis or Avastin.

19. The method of claim 16, wherein the pharmacological agent is Triamcinolone, Ozurdex, VEGF-TRAP, or Visudyne.

20. The method of claim 1, wherein the retinal disease is dry macular degeneration disease and the user's visual function test data includes tests that are pre-selected to determine progression to wet macular degeneration disease.

21. The method of claim 1, wherein a frequency for performing each of the tests in the visual function test data are selected by the healthcare provider.

22. The method of claim 21, wherein the frequency is set by the health care provider based on the user's responses during a monitoring period or trends in the user's visual function.

23. The method of claim 1, wherein analyzing the trend data of visual function includes comparing the trends in the user's visual function to trends for other patients or groups of other patients.

24. The method of claim 1, wherein the visual function test data includes data from one or more visual function tests from the list: visual acuity, contrast sensitivity, low luminance vision, color vision, perimetry, and distortion in the visual field.

25. The method of claim 24, wherein a level of difficulty for a subsequent step in the visual function test is higher than a level of difficulty for a previous step when the user enters a correct response in the previous step, wherein the level of difficulty for the subsequent step is lower than the level of difficulty in the previous step when the user enters an incorrect response in the previous step.

26. The method of claim 24, wherein visual acuity is measured by sequentially displaying fonts of various sizes and offering a multiple choice of fonts for a matching selection.

27. The method of claim 24, wherein contrast sensitivity is measured by sequentially displaying fonts of various colors and offering a multiple choice of fonts for a matching selection.

28. The method of claim 24, wherein the contrast sensitivity test begins with a pre-selected background color and a pre-selected font color, wherein the background color or font color changes to decrease a contrast between the background color and font color.

29. The method of claim 1, wherein the visual function test data corresponds to one or more tests selected by the healthcare provider using a remote server, and transmitting the selection of the one or more tests to the user's mobile device.

30. The method of claim 1, further comprising automatically re-testing the user if the visual function test data is outside of a range of acceptable variation for the user.

31. The method of claim 1, wherein the retinal diseases include one or more conditions from the list: macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, glaucoma, and chronic retinal detachment.

32. A system for performing a visual function analysis, comprising: a processor; a memory; a test data analysis module stored in memory and executable by the processor to generate trend data from visual function test data received from a remote mobile device associated with a user having a retinal disease and receiving recurrent treatment from a healthcare provider, the test data analysis module further configured to analyze the trend data from visual function test data to determine if a next treatment is to be scheduled and predicting a time for the next treatment for the user based on the trend data; an I/O interface module stored in memory and executable by the processor to send trend data, a predicted time for the next treatment, and a physician message to the remote mobile device.

33. The system of claim 32, wherein the visual function test data corresponds to tests that were pre-selected for the user by the user's healthcare provider and performed by the user using the remote mobile device.

Details for Patent 9,572,484

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2031-10-17 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2031-10-17 RX Orphan search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) 2031-10-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Boehringer Ingelheim
McKesson
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.